In Episode 27 of Hims House, Jonathan Stern, Patrick Lester, and Louis Stevens discuss the blockbuster news of Hims partnering with Novo Nordisk to sell branded GLP-1 medication Wegovy for $599 a month. They delve into the deal terms, initial market reaction, and the potential long-term impacts on Hims as the direct-to-consumer telehealth leader. The conversation also touches on the possibility of future partnerships, notably with Eli Lilly, and how Hims' business model and profit margins might evolve.

00:00 Introduction

01:46 Patrick's Perspective on the Deal

08:09 Louis' Return and Reflections

09:58 Comparing Hims to Netflix and Long-term Prospects

15:46 Impact on Bear Thesis and Revenue Projections

21:12 Understanding Hims as an AI-Orchestrated General Physician

27:01 Wall Street's Obsession with GLP-1s

31:30 Margin Impact of the Novo Deal

40:01 Future Partnerships and 2025 Outlook

Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions

Get full access to Hims House at himshouse.substack.com/subscribe